Douglas M Potter

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer
    Douglas M Potter
    University of Pittsburgh, University of Pittsburgh Cancer Institute, Biostatistics Facility, Suite 325, Sterling Plaza, 201 North Craig St, PA 15213, USA
    Stat Med 21:1805-23. 2002
  2. ncbi request reprint Omnibus permutation tests of the overall null hypothesis in datasets with many covariates
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15213, USA
    J Biopharm Stat 16:327-41. 2006
  3. ncbi request reprint Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, Cancer Institute, Pennsylvania 15213, USA
    J Biopharm Stat 16:579-604. 2006
  4. ncbi request reprint Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case-control studies
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Genet Epidemiol 30:438-46. 2006
  5. ncbi request reprint A permutation test for inference in logistic regression with small- and moderate-sized data sets
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Suite 325, Sterling Plaza, 201 North Craig Street, Pittsburgh, PA 15213, USA
    Stat Med 24:693-708. 2005
  6. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
  7. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
  8. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
  9. ncbi request reprint Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
  10. pmc AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients
    Viktoria N Evdokimova
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 30:425-37. 2007

Collaborators

Detail Information

Publications47

  1. ncbi request reprint Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer
    Douglas M Potter
    University of Pittsburgh, University of Pittsburgh Cancer Institute, Biostatistics Facility, Suite 325, Sterling Plaza, 201 North Craig St, PA 15213, USA
    Stat Med 21:1805-23. 2002
    ..4 on a target DLT probability of 0.3 is obtained over a wide variation in dose-response characteristics of the study drug. The performance of the new method is compared to that of rule-based methods...
  2. ncbi request reprint Omnibus permutation tests of the overall null hypothesis in datasets with many covariates
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15213, USA
    J Biopharm Stat 16:327-41. 2006
    ..We use simulations to investigate seven omnibus test statistics and find that the Anderson-Darling and Fisher's statistics are superior to the others...
  3. ncbi request reprint Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh and Biostatistics Facility, Cancer Institute, Pennsylvania 15213, USA
    J Biopharm Stat 16:579-604. 2006
    ..Rule-based designs can always determine a reasonable maximum tolerable dose based on observed toxicity, but when model assumptions are not satisfied, many model-guided designs will not...
  4. ncbi request reprint Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case-control studies
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Genet Epidemiol 30:438-46. 2006
    ....
  5. ncbi request reprint A permutation test for inference in logistic regression with small- and moderate-sized data sets
    Douglas M Potter
    Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Suite 325, Sterling Plaza, 201 North Craig Street, Pittsburgh, PA 15213, USA
    Stat Med 24:693-708. 2005
    ....
  6. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  7. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  8. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
  9. ncbi request reprint Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
    ..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week...
  10. pmc AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients
    Viktoria N Evdokimova
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 30:425-37. 2007
    ..Importantly, CD4 T-cell cytokine expression profiles were skewed towards interleukin-2 and interferon-gamma production when activated by adenovirally engineered DC, which has therapeutic implications for vaccination efforts...
  11. ncbi request reprint Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors
    Laura L Jung
    Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
    Cancer Chemother Pharmacol 54:487-96. 2004
    ..Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part of phase I and phase II studies...
  12. pmc Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus
    Lazar Vujanovic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Immunol Immunother 58:121-33. 2009
    ..These data identify molecular changes in AdV-transduced DC (AdV/DC) that could influence T cell priming and should be considered in design of cancer vaccines...
  13. ncbi request reprint Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma
    George van Buren
    Division of Surgical Oncology, UPMC Pancreatic Cancer Center, Pittsburgh, PA, USA
    Ann Surg Oncol 20:3787-93. 2013
    ....
  14. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  15. doi request reprint Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer
    Benedito A Carneiro
    University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Colorectal Cancer 11:53-9. 2012
    ..Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC...
  16. ncbi request reprint Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 56:1931-43. 2007
    ....
  17. pmc Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 106:10746-51. 2009
    ..This study suggests development of novel miR-targeted therapy to promote cytolysis of tumor cells...
  18. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
    ..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC...
  19. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
    ..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
  20. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
  21. pmc Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer
    Yang Liu
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol 177:712-21. 2006
    ..These subdominant epitope-specific T cells can also recognize tumor cells and may be important therapeutically...
  22. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  23. doi request reprint A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer
    Rajesh Sehgal
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Clin Colorectal Cancer 10:117-20. 2011
    ..A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)...
  24. pmc MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
    Takashi Kimura
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 6:18-26. 2013
    ..g., high levels of MDSC) might already exist in some individuals, suggesting an even earlier premalignant stage or preselection of nonimmunosuppressed patients for prophylactic vaccination...
  25. pmc Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in
    Hideho Okada
    G12 a Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave, Pittsburgh, PA 15213 1863, USA
    J Clin Oncol 29:330-6. 2011
    ..GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100...
  26. ncbi request reprint Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors
    Kotaro Sasaki
    Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Res 67:6451-8. 2007
    ....
  27. ncbi request reprint Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells
    Stephen R Goding
    Department of Immunology, Graduate School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Hum Gene Ther 18:701-11. 2007
    ..These data show that the presence of IL-12 around tumor-infiltrating A-NK cells enhances their antitumor activity while reducing their requirement for systemically administered IL-2...
  28. pmc LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 19:1816-26. 2013
    ..In this study, we examined the prevalence of these LOH events and their relations with overall survival in GBM...
  29. pmc Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients
    Douglas M Potter
    Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
    J Immunol Methods 376:108-12. 2012
    ..We describe a new study of the association of serum biomarker level with overall survival in melanoma patients, and the problems encountered in carrying it out...
  30. pmc Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Transl Med 5:67. 2007
    ..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts...
  31. pmc Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 17:3064-76. 2011
    ..Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements...
  32. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  33. pmc Multiplex serum biomarker assessments: technical and biostatistical issues
    Lisa H Butterfield
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Transl Med 9:173. 2011
    ..Many of these studies seek biomarkers among circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been identified which can impact the resulting data...
  34. pmc Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer
    Ann Willman Silk
    University of Pittsburgh, School of Medicine and Clinical Scientist Training Program, Pittsburgh, PA 15232, United States
    Mol Immunol 47:52-6. 2009
    ..045 OD vs. 0.030 OD; p=0.017). Our data support further studies into the potential role of anti-MUC1 immunity in preventing progression of premalignant colon lesions to colon cancer...
  35. ncbi request reprint Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel
    Josephia R Muindi
    Center for Clinical Pharmacology and Cancer Institute, University of Pittsburgh, PA 15213, USA
    Clin Pharmacol Ther 72:648-59. 2002
    ..An additional goal was to evaluate the relationship between calcitriol dose and hypercalcemia...
  36. ncbi request reprint Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2992-9. 2002
    ..There was no relationship between Factor VIII expression and Pt exposure in tumors. The variable penetration of Pt from plasma into tumor ECF may be associated with variable response of tumors...
  37. ncbi request reprint Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 53:329-36. 2004
    ..Thus, we evaluated the disposition of encapsulated and released Pt in plasma and tumors after administration of STEALTH liposomal and nonliposomal cisplatin...
  38. pmc Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate
    Renaud Warin
    Department of Pharmacology, and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 69:9473-80. 2009
    ..The present study demonstrating efficacy of BITC against mammary cancer in an animal model provides impetus to determine its activity in a clinical setting...
  39. ncbi request reprint DNA repair pathways involved in anaphase bridge formation
    Ceyda Acilan
    Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Genes Chromosomes Cancer 46:522-31. 2007
    ..Moreover, intrinsic NHEJ activity of different cell lines appears to have a positive trend with induction of bridges from DNA damage...
  40. ncbi request reprint Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:4313-8. 2002
    ..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
  41. ncbi request reprint Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines
    Hideho Okada
    Departments of Neurological Surgery, University of Pittsburgh School of Medicine, PA 15213, USA
    Cancer Res 64:5830-8. 2004
    ..On the basis of these results, we believe that local expression of IFN-alpha by DCs within the intracranial tumor site may enhance the clinical efficacy of peripheral vaccine approaches for brain tumors...
  42. ncbi request reprint A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:2817-25. 2006
    ..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen...
  43. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Ramesh K Ramanathan
    Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
    J Clin Oncol 26:563-9. 2008
    ..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)...
  44. ncbi request reprint Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Cancer Chemother Pharmacol 56:492-6. 2005
    ..83). We conclude that the commercially available liquid 1,25-D(3) formulation offers no PK advantage over caplet formulation...
  45. ncbi request reprint Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 106:2136-42. 2006
    ..The combination of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) plus dexamethasone was studied based on evidence that dexamethasone potentiates the antitumor effects of calcitriol and ameliorates hypercalcemia...
  46. pmc Variability in cerebral oxygen delivery is reduced in premature neonates exposed to chorioamnionitis
    Toby D Yanowitz
    Department of Pediatrics, University of Pitttsburgh School of Medicine, PA 15217, USA
    Pediatr Res 59:299-304. 2006
    ..Further studies are needed to determine how these findings relate to cerebral blood flow autoregulation and oxygen utilization in premature infants...
  47. ncbi request reprint Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis
    Chris Kahlenborn
    Department of Internal Medicine, Altoona Hospital, Altoona, PA, USA
    Mayo Clin Proc 81:1290-302. 2006
    ..To perform a meta-analysis of case-control studies that addressed whether prior oral contraceptive (OC) use is associated with premenopausal breast cancer...